Trade Resources Industry Views Sutro Biopharma Has Entered Into a Collaboration Agreement

Sutro Biopharma Has Entered Into a Collaboration Agreement

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.

"Neuroblastoma is the most common extra-cranial solid tumor in children, and long-term survival for children with advanced disease diagnosed after 18 months of age is unsatisfactory despite aggressive chemotherapy," said Trevor Hallam, Ph.D., chief scientific officer of Sutro. "Sutro's technology allows the generation, and importantly, the rapid screening of a large number of variations of bispecific antibodies. This will enable us to take bispecific antibodies with the desired characteristics faster into the clinic and potentially provide pediatric neuroblastoma patients with a much needed effective treatment option to combat this disease."

Source: http://www.news-medical.net/news/20140107/Memorial-Sloan-Kettering-to-use-Sutros-cell-free-protein-synthesis-technology-to-produce-bispecific-antibodies.aspx
Contribute Copyright Policy
Memorial Sloan-Kettering to Use Sutro's Cell-Free Protein Synthesis Technology to Produce Bispecific Antibodies